Elite Trades From Anywhere

$100 Off Your First Year

Claim Now
Last Close
4.86
Jun 29 • 04:00PM ET Dollar change+0.05 Percentage change(1.04%)
Index
-
Market Cap
308.92M
Enterprise Value
259.91M
Income
-70.36M
Sales
157.08M
Book/sh
0.33
Cash/sh
2.43
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
293
IPO
Oct 10, 2013
P/E
-
Forward P/E
-
PEG
-
P/S
1.97
P/B
14.57
P/C
2.00
P/FCF
-
EV/EBITDA
-
EV/Sales
1.65
Quick Ratio
1.80
Current Ratio
1.90
Debt/Eq
4.96
LT Debt/Eq
4.72
Option/Short
Yes / Yes
EPS (ttm)
-1.11
EPS next Y
-1.23
EPS next Q
0.03
EPS this Y
22.47%
EPS next Y
-34.81%
EPS next 5Y
-3.15%
EPS past 3/5Y
15.37% 13.74%
Sales past 3/5Y
-0.54% 7.35%
EPS Y/Y TTM
-25.03%
Sales Y/Y TTM
1.97%
EPS Q/Q
11.06%
Sales Q/Q
57.48%
Insider Own
3.54%
Insider Trans
0.00%
Inst Own
69.90%
Inst Trans
4.01%
ROA
-31.80%
ROE
-140.27%
ROIC
-58.05%
Gross Margin
69.93%
Oper. Margin
-40.53%
Profit Margin
-44.79%
SMA20
14.81%
SMA50
25.89%
SMA200
100.95%
Trades
Shs Outstand
63.56M
Shs Float
61.32M
52W High
5.08 -4.33%
52W Low
1.18 310.13%
Volatility
8.43% 7.17%
ATR (14)
0.32
RSI (14)
67.77
Beta
1.14
Rel Volume
1.19
Avg Volume
1.14M
Volume
1,360,551
Perf Week
6.11%
Perf Month
15.44%
Perf Quarter
65.87%
Perf Half Y
200.00%
Perf YTD
201.86%
Perf Year
308.40%
Perf 3Y
-6.72%
Perf 5Y
-81.80%
Perf 10Y
-81.94%
Prev Close
4.81
Price
4.86
Change
1.04%
Date Action Analyst Rating Change Price Target Change
Apr-10-26Upgrade B. Riley Securities Neutral → Buy $9
Sep-17-25Resumed Barclays Overweight $3
Nov-07-24Downgrade JMP Securities Mkt Outperform → Mkt Perform
Aug-01-24Downgrade BTIG Research Buy → Neutral
Jul-31-24Downgrade Guggenheim Buy → Neutral
Jul-31-24Downgrade B. Riley Securities Buy → Neutral $18 → $5
May-10-24Downgrade TD Cowen Buy → Hold
May-10-24Downgrade Stifel Buy → Hold $29 → $7
May-10-24Downgrade BMO Capital Markets Outperform → Market Perform $24 → $8
Apr-26-24Initiated B. Riley Securities Buy $25
Jun-22-26 04:43PM
May-28-26 06:33PM
12:53PM
May-14-26 04:01PM
May-13-26 04:26PM
04:01PM Loading…
04:01PM
May-12-26 11:08AM
May-11-26 05:20PM
May-04-26 07:30AM
Apr-08-26 04:30PM
Mar-09-26 05:15PM
04:23PM
04:01PM
Feb-26-26 06:00PM
05:30PM
06:16AM Loading…
Feb-24-26 06:16AM
Feb-23-26 06:14PM
Jan-13-26 09:19AM
Jan-05-26 10:26AM
Nov-25-25 04:05PM
Nov-12-25 05:15PM
04:07PM
04:01PM
Nov-10-25 09:55AM
Nov-06-25 04:30PM
Oct-30-25 05:30PM
Sep-02-25 04:30PM
Aug-14-25 05:15PM
04:10PM
04:01PM
04:01PM Loading…
Aug-13-25 04:01PM
08:50AM
Jul-31-25 07:25AM
Jul-29-25 05:10PM
Jun-10-25 07:00AM
Jun-03-25 04:30PM
May-22-25 09:36AM
May-21-25 11:37AM
May-13-25 05:15PM
04:11PM
04:01PM
May-12-25 09:46AM
07:15AM
May-08-25 07:40AM
May-07-25 05:40PM
May-06-25 04:30PM
May-01-25 04:30PM
Apr-17-25 08:52AM
Apr-03-25 09:35AM
Mar-21-25 02:19PM
12:05PM
09:29AM
03:05AM
Mar-20-25 08:15PM
07:09PM
07:00PM
06:50PM
04:02PM
10:00AM
Mar-19-25 05:35PM
05:15PM
Mar-06-25 07:30AM
Feb-27-25 07:30AM
Dec-02-24 04:30PM
Nov-06-24 04:30PM
08:51AM
02:25AM
Nov-05-24 10:15PM
08:00PM
07:30PM
06:26PM
04:01PM
Nov-04-24 07:13AM
Oct-30-24 07:30AM
Oct-29-24 04:30PM
Oct-23-24 08:41AM
Oct-22-24 07:30AM
Sep-24-24 05:45AM
Sep-23-24 11:05AM
Sep-20-24 05:06AM
Sep-19-24 01:29PM
Sep-17-24 08:30AM
05:45AM
Sep-15-24 03:00AM
Sep-13-24 08:34AM
Sep-11-24 08:30AM
Sep-08-24 07:10PM
Sep-04-24 03:29PM
Sep-03-24 05:45AM
Sep-02-24 02:05PM
Aug-30-24 09:43AM
Aug-29-24 01:09PM
Aug-27-24 10:48AM
Aug-26-24 03:40PM
Aug-22-24 03:16PM
01:17PM
Aug-21-24 07:05AM
Aug-19-24 04:37PM
Aug-17-24 03:29PM
Aug-16-24 05:45AM
MacroGenics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of antibody-based therapeutics for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.
CEOMr. Eric Blasius Risser
Senior VP & CFOMr. James Karrels
Senior VP of Research & Chief Scientific OfficerDr. Ezio Bonvini M.D.
Senior Vice President of Technical OperationsDr. Thomas M. Spitznagel Ph.D.
Senior VPMr. Jeffrey Stuart Peters J.D.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Koenig ScottDirectorFeb 15 '26Option Exercise0.0021,1650867,240Feb 17 06:22 PM
HEIDEN WILLIAM KDirectorAug 19 '25Buy1.5250,50076,76061,500Aug 21 04:19 PM
HEIDEN WILLIAM KDirectorAug 20 '25Buy1.4949,50073,755111,000Aug 21 04:19 PM
Koenig ScottDirectorAug 13 '25Option Exercise0.0052,8290830,244Aug 15 05:05 PM